Inhibition of the norepinephrine transporter rescues vascular hyporeactivity to catecholamine in obstructive jaundice

Mo Chen,Yan Zhang,Hongqian Wang,Hao Yang,Wen Yin,Saihong Xu,Tao Jiang,Mansi Wang,Feixiang Wu,Weifeng Yu
DOI: https://doi.org/10.1016/j.ejphar.2021.174055
IF: 5.195
2021-06-01
European Journal of Pharmacology
Abstract:<p>In patients with obstructive jaundice, the cardiovascular system exhibits hypotension and vascular hyporeactivity. Most norepinephrine is taken up through the neuronal norepinephrine transporter (NET), which is implicated in cardiovascular diseases. A previous study demonstrated that pharmacological NET inhibition could increase resting blood pressure. However, the role of NETs in vascular hyporeactivity induced by obstructive jaundice is poorly understood. This study used the NET inhibitor nisoxetine and a rat model of bile duct ligation (BDL) to investigate whether NET is associated with BDL-induced vascular hyporeactivity. Rats were injected with nisoxetine via the tail vein for 7 consecutive days after BDL. Samples of the superior cervical sympathetic ganglion (SCG) and thoracic aortic rings were processed for investigations. Our results showed that NET expression in the SCG was significantly increased after BDL. Nisoxetine prevented the augmentation of NET expression, increased α<sub>1</sub>-adrenoceptor activation, and enhanced the weakened contractile responses of thoracic aortic rings after BDL. Our study demonstrates that nisoxetine plays a protective role in BDL-induced vascular hyporeactivity through increased α<sub>1</sub>-adrenoceptor activation in rats.</p>
pharmacology & pharmacy
What problem does this paper attempt to address?